ethyl 2-(3-mercaptophenyl)acetate | 123964-00-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: ethyl 2-(3-mercaptophenyl)acetate
• 英文别名: ethyl 2-(3-sulfanylphenyl)acetate；3-mercaptophenylacetic acid ethyl ester；ethyl 3-mercaptophenyl acetate；(3-Mercapto-phenyl)-acetic acid ethyl ester
• CAS: 123964-00-1
• 化学式: C₁₀H₁₂O₂S
• 分子量: 196.27
• InChiKey: JEINORNTPIIWCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  27.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-(3-mercaptophenyl)acetate 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 ethyl 2-(3-((4-aminophenyl)sulfonyl)phenyl)acetate
  参考文献：
  名称：

  [EN] 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物的方法。

  公开号：

  WO2017156181A1
• 作为产物：
  描述：

  3-溴苯乙酸乙酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 、 三异丙基硅烷硫醇 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 ethyl 2-(3-mercaptophenyl)acetate
  参考文献：
  名称：

  [EN] 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE LA 3-PHOSPHOGLYCÉRATE DÉSHYDROGÉNASE ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物的方法。

  公开号：

  WO2017156181A1

文献信息

• [EN] ROR GAMMA (RORY) MODULATORS<br/>[FR] MODULATEURS DU ROR GAMMA (RORY)
  申请人：LEAD PHARMA CEL MODELS IP B V

  公开号：WO2015082533A1

  公开（公告）日：2015-06-11

  The present invention relates to compounds according to Formula I: Wherein: A11 - A14 are N or CR11, CR12, CR13, CR14, respectively, with the proviso that no more than two of the four positions A can be simultaneously N; R1 is C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, (di)C(1-6)alkylamino, (di)C(3-6)cycloalkylamino or (di)(C(3-6)cycloalkylC(1 -3)alkyl)amino, with all carbon atoms of alkyl groups optionally substituted with one or more F and all carbon atoms of cycloalkyl groups optionally substituted with one or more F or methyl; R2 and R3 are independently H, F, methyl, ethyl, hydroxy, methoxy or R2 and R3 together is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; R4 is H or C(1-6)alkyl; R5 is H, hydroxyethyl, methoxyethyl, C(1-6)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1 -9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1 -3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano; the sulfonyl group with R1 is represented by one of R7, R8 or R9; the remaining R6-RH are independently H, halogen, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl, all of the alkyl groups optionally being substituted with one or more F; and Ri5 and Ri6 are independently H, C(1-6)alkyl, C(3-6)cycloalkyl, C(3-6)cycloalkylC(1-3)alkyl, C(6-10)aryl, C(6-10)arylC(1-3)alkyl, C(1-9)heteroaryl, C(1-9)heteroarylC(1-3)alkyl, C(2-5)heterocycloalkyl or C(2-5)heterocycloalkylC(1-3)alkyl, all groups optionally substituted with one or more F, CI, C(1-2)alkyl, C(1-2)alkoxy or cyano. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.

  本发明涉及符合以下式I的化合物：其中：A11 - A14分别为N或CR11，CR12，CR13，CR14，但四个位置A中不超过两个可以同时为N；R1为C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，(双)C(1-6)烷基氨基，(双)C(3-6)环烷基氨基或(双)(C(3-6)环烷基C(1-3)烷基)氨基，烷基族的所有碳原子可选择性地被一个或多个F取代，环烷基族的所有碳原子可选择性地被一个或多个F或甲基取代；R2和R3独立地为H，F，甲基，乙基，羟基，甲氧基或R2和R3一起为羰基，所有烷基族（如果存在）可选择性地被一个或多个F取代；R4为H或C(1-6)烷基；R5为H，羟乙基，甲氧乙基，C(1-6)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代；与R1相连的磺酰基由R7，R8或R9之一表示；其余的R6-RH独立地为H，卤素，C(1-3)烷氧基，(双)C(1-3)烷基氨基或C(1-6)烷基，所有烷基族可选择性地被一个或多个F取代；Ri5和Ri6独立地为H，C(1-6)烷基，C(3-6)环烷基，C(3-6)环烷基C(1-3)烷基，C(6-10)芳基，C(6-10)芳基C(1-3)烷基，C(1-9)杂环芳基，C(1-9)杂环芳基C(1-3)烷基，C(2-5)杂环烷基或C(2-5)杂环烷基C(1-3)烷基，所有基团可选择性地被一个或多个F，CI，C(1-2)烷基，C(1-2)烷氧基或氰取代。这些化合物可用作RORγ的抑制剂，并且对于治疗RORγ介导的疾病是有用的。
• Synthesis and antiinflammatory activity of cis- and trans-6,6a,7,8,9,10,10a,11-octahydro-11-oxodibenzo[b,e]thiepinacetic and -oxepinacetic acids
  作者：Mikio Kurokawa、Hitoshi Uno、Hideo Nakamura、Fuminori Sato、Shunsuke Naruto

  DOI：10.1021/jm00164a006

  日期：1990.2

  A series of cis- and trans-6,6a,7,8,9,10,10a,11-octahydro-11- oxodibenzo[b,e]thiepinacetic acids (6-9) and -oxepinacetic acids (10-13) were prepared and their antiinflammatory activity was examined in the rat carrageenan hind paw edema test. The antiinflammatory activity of these compounds depended on their stereochemical features (C6a, C10a, and C2'). The 6a,10a-trans compounds exhibited considerable

  一系列顺式和反式-6,6a，7,8,9,10,10a，11-八氢-11-氧二苯并[b，e]噻吩乙酸（6-9）和-氧庚乙酸（10-13）在大鼠角叉菜胶后爪水肿试验中制备了它们的制剂并检查了它们的抗炎活性。这些化合物的抗炎活性取决于其立体化学特征（C6a，C10a和C2'）。6a，10a-反式化合物表现出相当大的抗炎活性，而6a，10a-顺式化合物则没有活性。在反式化合物中，6,6a，7,8,9,10,10a，11-八氢-11-氧代二苯并[b，e] thiepin-3-p丙酸（9a）及其oxepin类似物（13a）显示消炎活性优于消炎痛。9a的苯乙酯（25）具有强效的抗炎活性，其安全指数（UD50 / ED50）比消炎痛高14倍以上。
• [EN] COMPOUNDS WHICH ARE MODULATORS OF THE PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSES FONCTIONNANT COMME MODULATEURS DE RECEPTEURS DE TYPE PPAR ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
  申请人：GALDERMA RES & DEV

  公开号：WO2004072022A1

  公开（公告）日：2004-08-26

  The invention relates to novel compounds which correspond to the following general formula (I): their method of preparation, and their use in pharmaceutical compositions intended for use in human or veterinary medicine (in dermatology and in the field of cardiovascular diseases, immune diseases and/or diseases linked to lipid metabolism), or in cosmetic compositions.

  该发明涉及与以下一般式（I）相对应的新化合物，它们的制备方法，以及它们在用于人类或兽医药物组合物中的用途（在皮肤病学和心血管疾病、免疫疾病和/或与脂质代谢相关的疾病领域），或者在化妆品组合物中的用途。
• Prostaglandin derivatives
  申请人：Sato Fumie

  公开号：US20060270740A1

  公开（公告）日：2006-11-30

  A prostaglandin derivative represented by the formula (wherein X is a halogen atom; Y is ethylene group, vinylene group or ethylylene group; Z is a group represented by —(CH 2 ) m , —O(CH 2 ) n — or —S(O) p —(CH 2 ) n — (m is an integer of 0 to 3; n is an integer of 0 to 2; and p is an integer of 0 to 2); R 1 is a hydrogen atom, a C 1-5 alkyl group or a substituted C 1-5 alkyl group; R 2 is a C 3-10 cycloalkyl group, a C 3-10 cycloalkyl group substituted by C 1-4 alkyl group or C 4-15 cycloalkylalkyl group; and R 3 is a hydrogen atom, a halogen atom or a C 1-5 alkyl group or a substituted C 1-5 alkyl group), a pharmaceutically acceptable salt thereof or a hydrate thereof which has an excellent antagonism to prostaglandin DP receptor and, therefore, is useful against diseases such as allergic rhinitis, nasal obstruction, asthma, allergic conjunctivitis, systemic mastocytosis and disorder of systemic mast cell activation.

  一种前列腺素衍生物，其化学式为：其中X为卤素原子；Y为乙烯基，乙烯基或乙基基；Z为由-(CH2)m，-O(CH2)n-或-S(O)p-(CH2)n-表示的基团（其中m为0至3的整数；n为0至2的整数；p为0至2的整数）；R1为氢原子，C1-5烷基或取代的C1-5烷基；R2为C3-10环烷基，C3-10环烷基被C1-4烷基或C4-15环烷基烷基取代；R3为氢原子，卤素原子或C1-5烷基或取代的C1-5烷基，其药物可接受的盐或水合物对前列腺素DP受体具有优异的拮抗作用，因此对过敏性鼻炎，鼻塞，哮喘，过敏性结膜炎，系统性肥大细胞病和系统性肥大细胞激活障碍等疾病有用。
• AUTOTAXIN INHIBITORS AND USES THEREOF
  申请人：Roppe Jeffrey Roger

  公开号：US20130150326A1

  公开（公告）日：2013-06-13

  Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.

  本文介绍了一些抑制自体脂肪酶的化合物。还介绍了包括上述化合物的药物组合物和药物，以及使用这些抑制剂的方法，单独或与其他化合物结合，用于治疗依赖或介导自体脂肪酶的疾病或症状。